SEC Form 4 · accession 0001213900-19-004003
ADIAL PHARMACEUTICALS, INC. · ADIL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Truluck
Officer — Chief Financial Officer
Period of report
Mar 10, 2019
Accepted (ET)
Mar 12, 2019 · 6:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001513525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $3.39 | Mar 10, 2019 | A | 180,000 | A | Apr 10, 2019 | Mar 9, 2029 | Common Stock | 180,000 | 180,000 | D |
Explanation of responses
- F1These options vest pro rata on a monthly basis over 36 months.